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nuric range in type 2 diabetic and nondiabetic individuals.Inflammation and microalbuminuria in nondiabetic and type
Chronic inflammation therefore emerges as a potential media-2 diabetic subjects: The Insulin Resistance Atherosclerosis
tor between microalbuminuria and macrovascular disease.Study.
Background. Microalbuminuria is a risk factor for cardio-
vascular disease, but the underlying pathomechanisms are still
poorly understood. A relationship between C-reactive protein Microalbuminuria, defined as an increased urinary al-(CRP), a sensitive marker of inflammation, and atherosclerotic
bumin excretion rate in the absence of clinically compro-disease has been reported recently.
mised renal function, is a strong risk factor for overtMethods. We hypothesized that microalbuminuria might be
associated with chronic inflammation and investigated the rela- nephropathy in patients with type 1 diabetes [1, 2]. In
tionship of urinary albumin excretion, as assessed from the contrast, in patients with type 2 diabetes, microalbumi-
albumin-to-creatinine ratio (ACR), in an untimed morning nuria predicts cardiovascular rather than renal disease
urine specimen, and two inflammatory markers (CRP and fi-
[3–7]. In nondiabetic subjects, microalbuminuria was as-brinogen) in the large, triethnic population of the Insulin Resis-
sociated with excess early [8] and long-term [9–11] car-tance Atherosclerosis Study (IRAS). After exclusion of sub-
jects with macroalbuminuria, 1481 subjects were studied. diovascular mortality. The reasons for the increased car-
Results. Both inflammatory markers were related to urinary diovascular risk in subjects with microalbuminuria are
ACR (r 5 0.17 for CRP and r 5 0.14 for fibrinogen, both P 5 largely unknown. It has been suggested that microalbum-
0.0001), an association that remained significant after adjust-
inuria generally reflects a state of widespread endothelialment for demographic variables, diabetic status, smoking, and
dysfunction and/or vascular damage [12].use of angiotensin-converting enzyme inhibitors (P , 0.01).
Mean levels of CRP and fibrinogen were elevated in microal- Recently, a relationship between C-reactive protein
buminuric (N 5 262) versus normoalbuminuric (N 5 1219) (CRP), a sensitive marker of inflammation, and the de-
subjects (5.37 6 0.47 vs. 3.80 6 0.15 mg/L and 295.7 6 4.0 vs. velopment of atherosclerotic disease has been observed
278.2 6 1.6 mg/dL, both P , 0.0001). The associations were
in experimental [13–15] and clinical studies [16–23].consistent among nondiabetic and type 2 diabetic subjects and
While it is still unknown whether elevated CRP levelsamong the three ethnic groups of the IRAS (non-Hispanic
whites, blacks, Hispanics). In a logistic regression model, fi- [and/or its main stimulator interleukin-6 (IL-6)] are the
brinogen was independently associated with microalbuminuria result of prevalent atherosclerotic disease or are actively
(P 5 0.047), along with hypertension, female gender, waist involved in the initiation and/or progression of disease,
circumference, and fasting blood glucose, while CRP was not
the latter seems likely given the known functions of CRPindependently related to microalbuminuria in this model (P 5
[15, 24] and the recently identified role of IL-6 in mouse0.26).
Conclusion. We have shown an association of CRP and fi- models [25].
brinogen with urinary albumin excretion in the microalbumi- In the present study, we hypothesized that microal-
buminuria in type 2 diabetic and nondiabetic subjects
might be related to markers of chronic inflammation,Key words: cardiovascular disease, albumin-to-creatinine ratio, C-reac-
such as CRP. Previously, inflammatory markers weretive protein, urinary albumin excretion, nephropathy, end-stage renal
disease. elevated in subjects with end-stage renal disease [23];
however, knowledge about a possible relationship ofReceived for publication September 9, 1999
inflammation with albumin excretion in the non-nephro-and in revised form February 5, 2000
Accepted for publication April 18, 2000 pathic range is limited and controversial. In type 1 dia-
betic subjects with microalbuminuria and macroalbu-Ó 2000 by the International Society of Nephrology
1703
Festa et al: Inflammation and microalbuminuria1704
minuria, no differences in CRP levels, compared with were asked prior to each visit to fast for 12 hours, to
abstain from heavy exercise and alcohol for 24 hours,normoalbuminuric patients and healthy controls, were
observed [26]. In type 2 diabetes, serum levels of sialic and to refrain from smoking the morning of the examina-
tion. A standard 75 g oral glucose tolerance test wasacid, another inflammatory marker, were elevated with
increasing albumin excretion in one study [27], but were performed, and the glucose tolerance status was based
on the World Health Organization criteria [37].unrelated to microalbuminuria in another [28].
A potential mediator of urinary albumin excretion as Insulin sensitivity was assessed by a FSIGT [38] with
minimal model analysis [39]. Two modifications of thewell as cardiovascular disease is increased insulin resis-
tance, which has been associated with microalbuminuria original protocol were used. An injection of regular insu-
lin, rather than tolbutamide, was used to ensure adequatein diabetic subjects [29–31], their relatives [32], and non-
diabetic subjects [33]. More recently, insulin resistance plasma insulin levels for the accurate computation of
insulin sensitivity across a broad range of glucose toler-has also been related to inflammatory markers [34, 35].
In the present study, we investigated the relationship ance [40], including diabetic patients because of their
blunted or absent insulin response. In addition, the re-of microalbuminuria to inflammatory markers in a large
triethnic population of type 2 diabetic and nondiabetic duced sampling protocol (which required 12 rather than
30 plasma samples and shows results similar to the fullindividuals. We included potential confounding factors
that were associated with albumin excretion and/or in- protocol) [41] was used because of the large number
of subjects. Insulin sensitivity, expressed as the insulinflammation in previous studies, including insulin resis-
tance, as directly measured by a frequently sampled sensitivity index (SI), was calculated by mathematical
modeling methods (MINMOD, version 3.0, 1994). Thisintravenous glucose tolerance test (FSIGT), blood pres-
sure (BP), and measures of body fat mass (BMI) and modified version of the FSIGT protocol used in the
IRAS has been compared with the hyperinsulinemic eu-body fat distribution (waist circumference).
glycemic clamp and has been shown to be an adequate
estimate of insulin resistance [42].
METHODS
Laboratory measurementsThe Insulin Resistance Atherosclerosis Study (IRAS)
is a multicenter epidemiologic study exploring relation- Urinary albumin and creatinine concentrations were
ships between insulin resistance, cardiovascular risk fac- assessed in a random morning spot urine sample. Urinary
tors, and cardiovascular disease across different ethnic albumin was measured from samples stored at 2208C
groups and varying states of glucose tolerance. A full by a commercial immunoprecipitation assay (Incstar
description of the design and methods of the IRAS has SPQ test system, Stillwater, MN, USA) with a sensitivity
been published previously [36]. The IRAS protocol was of 5.8 mg/L and intra-assay and interassay coefficients
approved by local institutional review committees, and of variation of 1.50 and 1.80%, respectively. Urinary
all subjects gave informed consent. creatinine was determined by a modified Jaffe method
A total of 1625 individuals participated in the IRAS. [43]. Urinary albumin and creatinine for all samples were
Subjects with a current acute illness (including clinically measured at the central IRAS laboratory at the Medlan-
significant infectious disease) were excluded from IRAS tic Research Institute (Washington, D.C., USA). From
examination. Urinary albumin excretion in the normoal- 170 blind duplicate specimens, the external coefficient
buminuric and microalbuminuric range was the scope of of variation was 12% for urinary albumin measurements
the present report; therefore, subjects with macroalbu- and 17% for urinary creatinine measurements; the corre-
minuria [albumin-to-creatinine ratio (ACR) $ 20 mg/ lation between the two blind duplicate measurements
mmol] were excluded from the analyses. Thus, this report was 0.82 for urinary albumin and 0.71 for urinary creati-
includes data on 1481 subjects, in whom the ACR as nine [33]. The urinary ACR (albumin in milligrams per
well as CRP and fibrinogen levels were assessed. Height liter and creatinine in millimoles per liter) was used as
and weight were measured following a standardized pro- a measure of albumin excretion. Overnight ACR corre-
tocol. Body mass index [weight/height2 (kg/m2)] was used lates well with urinary albumin excretion [44, 45], and
as an estimate of overall adiposity, and the minimum ACR measured in a single untimed urine specimen has
waist circumference was considered an estimate of vis- been shown to be an effective means for identifying
ceral fat mass. Cigarette smoking was dichotomized into diabetic patients who are at risk of developing overt
“never” and “ever” (including past and current) using a nephropathy [46]. An overnight ACR $2 mg/mmol pre-
standard questionnaire. BP was measured according to dicts an albumin excretion rate .30 mg/min with a high
a standard procedure, and hypertension was defined as sensitivity and specificity [44]. Microalbuminuria was de-
systolic BP $140 mm Hg and/or diastolic BP $90 mm Hg fined as ACR between 2 and 20 mg/mmol [33].
or current use of antihypertensive medication. C-reactive protein was measured by in-house ultra-
sensitive competitive immunoassay (antibodies and anti-The IRAS examination required two visits. Patients
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Table 1. Characteristics of the normo- (MAB2), andgens from Calbiochem, La Jolla, CA, USA) with an
microalbuminuric (MAB1) subjects in the Insulin Resistance
interassay CV of 8.9% [47]. Fibrinogen was measured Atherosclerosis Study (IRAS)
in citrated plasma with a modified clot-rate assay using
MAB2 MAB1 P valuethe Diagnostica STAGO ST4 instrument, as described
N 1219 262previously [48]. This was based on the original method
Diabetic/nondiabetic % 28/72 48/52 0.0001
of Clauss with a CV of 3.0% [49]. Samples for fibrinogen Hypertensive/nonhypertensive % 35/65 52/48 0.0001
Smokers/nonsmokers % 44/56 41/59 NSand CRP were prepared, frozen, and stored at 2708C at
Women/men % 54/46 63/37 0.01the clinical centers not later than 90 minutes after blood
Age years 55.560.2 55.960.5 NSdrawing. Frozen samples were shipped on a monthly
BMI kg/m2 29.160.2 31.260.4 0.0001basis to the Laboratory for Clinical Biochemistry Re- Waist cm 92.560.4 97.661.0 0.0001
search, University of Vermont (Burlington, VT, USA), SBP mm Hg 120.560.5 128.761.1 0.0001
DBP mm Hg 76.860.2 79.460.6 0.0001where measurements were performed. Glucose and insu-
Fasting glucose mg/dL 118.261.2 141.963.9 0.0001lin levels were measured as published previously [50]. SI 31024 min21 ·lU21 ·mL21 1.7960.06 1.1660.08 0.0001
Urinary albumin mg/L 8.3860.2 41.662.9 0.0001Statistical analyses
ACR mg/mmol 0.8060.01 4.9360.22 0.0001
Statistical analyses were performed using the SAS sta- CRP mg/L 3.8060.15 5.3760.47 0.0018
tistical software system. We analyzed urinary albumin ex- Fibrinogen mg/dL 278.261.6 295.764.0 0.0001
cretion as a continuous (ACR) as well as a dichotomous Values are means 6 SE. Differences between MAB2 and MAB1 were
calculated by Student’s t-test and chi-square test as appropriate.(normoalbuminuria vs. microalbuminuria) variable. Spear-
Abbreviations are: N, number of study subjects; BMI, body mass index; SBP,man rank correlations were calculated between ACR systolic blood pressure; DBP, diastolic blood pressure; SI, insulin sensitivity index;
ACR, albumin-to-creatinine ratio; CRP, C-reactive protein.and fibrinogen and CRP (Table 2). Stepwise partial rank
correlations were performed adjusting for age, gender,
ethnicity, clinic, and diabetic status (model B), smoking,
use of angiotensin-converting enzyme (ACE) inhibitors
and finally log of CRP or fibrinogen (Table 4). All analy-(model C), BMI, waist (model D), hypertension (model
ses were performed in the overall population and wereE), and SI (model F). These analyses were performed to also stratified by gender, ethnicity, and diabetic status.determine the extent to which a relationship was altered
We also tested for possible interactions of gender, eth-after adjusting for potentially confounding covariates,
nicity, and diabetic status, respectively, on the associa-previously shown to be related to albuminuria or in-
tion of urinary albumin excretion (ACR, microalbumi-flammatory marker or both. In the IRAS, previously we
nuria) with CRP and fibrinogen. We included in separatehave shown an association of SI and measures of body
models interaction terms for gender 3 ACR, gender 3fat and microalbuminuria [33], CRP [35], and fibrinogen
microalbuminuria, ethnicity 3 ACR, etc. These models[50], respectively. Glycemia and BP are important deter-
were adjusted for age, gender, ethnicity, clinic, and dia-minants of albuminuria [51], and smoking and use of
betic status. P values of less than 0.05 (two sided) wereACE inhibitors [51] are further potential determinants.
considered statistically significant.Smoking has also been related to CRP levels [18, 22].
Next, to compare mean values of CRP and fibrinogen
in subjects with normoalbuminuria versus microalbumi- RESULTS
nuria, analysis of variance (ANOVA) and analysis of
Table 1 shows the descriptive data stratified by albu-covariance (ANCOVA) were performed (Table 3). For
minuria status. Type 2 diabetes, hypertension, and fe-these analyses as well as the interaction models, logarith-
male gender were more prevalent among subjects withmically transformed values of CRP were used because
microalbuminuria. Subjects with microalbuminuria hadthe distribution of the residuals from the fitted models
higher ACR, BMI, waist circumference, fasting glucose,became normally distributed after log transformation.
CRP, and fibrinogen, and lower SI.Unadjusted and adjusted means for log of CRP (shown
back-transformed on Table 3) and fibrinogen were calcu-
Urinary albumin excretion as a continuouslated using analogous stepwise adjustments as for the
variable (ACR)Spearman rank correlations. Finally, to determine the
Both CRP and fibrinogen were significantly related torelative contribution of variables to urinary albumin ex-
ACR in the overall population (Table 2). The associationcretion, a logistic regression analysis with microalbumi-
was somewhat weakened after adjusting for demographicnuria as the outcome variable was performed. Two anal-
variables and diabetic status (model B) and slightly furtherogous models for log of CRP and fibrinogen were fit.
after adjustment for measures of body fat (model D), andIndependent variables were age, gender, ethnicity, clinic,
hypertension (model E), but adjustment for smoking,diabetic status, smoking, use of ACE inhibitors, BMI,
waist circumference, hypertension, fasting glucose, SI, use of ACE inhibitors, and SI had no substantial effect
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Table 3. Mean values of inflammatory markers according to theTable 2. Unadjusted (model A) and partial (models B–F) Spearman
correlation coefficients of albumin-to-creatinine ratio (ACR) albuminuria status (MAB1, microalbuminuria; MAB2,
normoalbuminuria) in the overall populationand inflammatory markers
Adjustment models CRP Fibrinogen Fibrinogen
CRP mg/L mg/dL
AdjustmentA: Unadjusted 0.17a 0.14a
B: Age, gender, ethnicity, clinic, diabetic status 0.09b 0.08b models MAB1 MAB2 P value MAB1 MAB2 P value
C: 1Smoking, ACE inhibitors 0.09b 0.08b
A 2.94 2.01 0.0001 295.7 278.2 0.0001D: 1BMI, waist 0.07c 0.07c
B 2.80 2.23 0.0012 293.2 280.2 0.0007E: 1Hypertension 0.06c 0.06c
C 2.80 2.20 0.0010 293.7 280.4 0.0005F: 1SI 0.06c 0.06c D 2.39 2.12 0.08 287.3 278.4 0.016
Overall population (N 5 1481). E 2.36 2.18 0.20 287.0 279.4 0.041
Covariates as shown were fit into the respective models in addition to all F 2.29 2.10 0.24 286.5 278.9 0.049
covariates included in the previous models in order to demonstrate to what
Adjustment models include: A, unadjusted; B, age, gender, ethnicity, clinic,extent the relation of inflammatory markers to albuminuria was attenuated by
diabetic status; C, 1 smoking, ACE inhibitors; D, 1 BMI, waist; E, 1 hyperten-the respective covariates.
sion; and F, 1 SI.Abbreviations are: CRP, C-reactive protein; ACE, angiotensin-converting
Covariates as shown were fit into the respective models in addition to allenzyme; BMI, body mass index; SI, insulin sensitivity.
covariates included in the previous models in order to demonstrate to whata P 5 0.0001, b P , 0.005, c P , 0.05
extent the relation of inflammatory markers to albuminuria was attenuated by
the respective co-variates. Abbreviations are in Table 1.
on the association (models C and F). A similar pattern
was also observed in the stratified analyses by gender, and 4). The differences were somewhat smaller after
ethnicity, and diabetic status (data not shown). adjusting for demographic variables and diabetic status
(Table 3, model B), measures of body fat (model D),Stratified analyses
and hypertension (model E). Further adjustment for SIBy gender. The association of ACR with both in- did not alter the results substantially (model F).
flammatory markers was significant in both men and in C-reactive protein and fibrinogen levels were also con-
women. Although the correlation was slightly stronger sistently higher in microalbuminuric subjects than in nor-
in men than in women, no significant interaction of gen-
moalbuminuric subjects when stratified by gender, eth-
der on the association of log CRP and fibrinogen with
nicity, and diabetic status (data not shown).ACR and microalbuminuria, respectively, was found (in-
Logistic regression analysis (Table 4) showed that hy-teraction terms: P 5 0.4 for both gender 3 microalbumi-
pertension, fasting glucose, waist circumference, andnuria and gender 3 ACR, respectively, on log CRP, and
gender were significant determinants of microalbuminu-P 5 0.7 and P 5 0.14 for gender 3 microalbuminuria
ria (when log of CRP was considered as an independentand gender 3 ACR, respectively, on fibrinogen).
variable in addition to age, gender, ethnicity, clinic, dia-By ethnicity. The association of ACR with both in-
betic status, smoking, use of ACE inhibitors, BMI, waistflammatory markers was significant in all three ethnic
circumference, hypertension, fasting glucose, and SI),groups of the IRAS. These associations were slightly
whereas gender, fasting glucose, hypertension, waist cir-more pronounced in blacks than in non-Hispanic whites
cumference, and fibrinogen were significantly related toand Hispanics; however, no significant interaction of eth-
microalbuminuria when fibrinogen was considered as annicity on the association of log CRP and fibrinogen with
additional independent variable (Table 4).ACR and microalbuminuria, respectively, was found (in-
teraction terms: P 5 0.11 and P 5 0.19 for ethnicity 3
microalbuminuria and ethnicity 3 ACR, respectively, DISCUSSION
on log CRP, and P 5 0.6 for both ethnicity 3 microal-
We report an association of chronic inflammation withbuminuria and ethnicity 3 ACR, respectively, on fibrin-
microalbuminuria in both nondiabetic and diabetic sub-ogen).
jects in the IRAS. The association was significant in menBy diabetic status. Correlation coefficients were com-
and in women and across the three ethnic groups of theparable in diabetic and nondiabetic subjects. Interaction
IRAS (blacks, non-Hispanic whites, Hispanics) and wasanalyses showed no significant interaction of diabetes
similar in magnitude in these subgroups as judged bystatus on the association of CRP and fibrinogen, respec-
the nonsignificant tests of interaction. The associationtively, with ACR and microalbuminuria, respectively
was moderately independent of confounding covariates(data not shown).
such as body fat, hypertension, and SI, although the
Urinary albumin excretion as a dichotomous variable: strong covariance in these variables makes it difficult to
Normoalbuminuria versus microalbuminuria estimate physiological independence statistically. Fur-
thermore, another variable (either unmeasured and/orInflammatory markers were higher in subjects with
microalbuminuria versus normoalbuminuria (Tables 3 not included in the multivariate models) might account
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Table 4. Logistic regression analysis with microalbuminuria as the dependent variable
Independent variable Odds ratio 95% CI P value
A. Log of CRP
Hypertension (0, no; 1, yes) 1.82 1.33, 2.47 0.0002
Fasting glucose 10 mg/dL increment 1.07 1.04, 1.08 0.0003
Waist circumference 5 cm increment 1.09 1.03, 1.16 0.0058
Gender (0, male; 1, female) 1.57 1.46, 1.68 0.0067
Log CRP 10% change 1.01 1.00, 1.02 0.26
B. Log of fibrinogen
Fasting glucose 10 mg/dL increment 1.07 1.03, 1.11 0.0001
Hypertension (0, no; 1, yes) 1.80 1.32, 2.45 0.0002
Waist circumference 5 cm increment 1.08 1.02, 1.15 0.0070
Gender (0, male; 1, female) 1.52 1.11, 2.08 0.0067
Fibrinogen 10 mg/dL increment 1.03 1.01, 1.04 0.047
After forcing age, gender, clinic, ethnicity, and diabetic status into the model, smoking status, use of ACE inhibitors, BMI, waist circumference, hypertension,
fasting glucose, SI, and log of CRP (A) or fibrinogen (B) were analyzed as independent variables. Only independent variables with a P value , 0.05 were left in the
final fitted model and are shown on the table (except log CRP in model A). CI is confidence interval.
for the relationships as shown acting as a yet unidentified than fibrinogen are scarce and conflicting. In type 2 dia-
betes, microalbuminuria was associated with elevatedmediating factor.
Few previous studies have reported associations of levels of fibronectin [61] and sialic acid [27], whereas in
another study, an association of microalbuminuria andinflammatory markers with urinary albumin excretion.
Studies investigating levels of fibrinogen in populations sialic acid was only found in 26 Chinese, but not in 29
Indian and 24 Malaysian individuals [62], and in anotherof healthy [52, 53], hypertensive [54], type 1 [26, 55–57],
and type 2 diabetic [57–60] populations have yielded small study (N 5 20), no association of microalbuminuria
with sialic acid was found at all [28]. CRP levels haveconflicting results. Elevations of fibrinogen levels in mi-
croalbuminuric versus normoalbuminuric subjects were only been studied in a small sample of type 1 diabetic
patients showing no significant increase in the presencefound in type 1 diabetes [56], Japanese type 2 diabetic
subjects [60], nondiabetic hypertensive subjects [54], and of microalbuminuria (N 5 22) versus normoalbuminuria
(N 5 17) [26].a general population [52]. Other studies report elevated
fibrinogen levels in subjects with albuminuria only in the C-reactive protein, because of its biological properties
(such as stable plasma levels over time) and the availabil-macroalbuminuric range in patients with type 1 [26, 55,
57] and type 2 diabetes [57]. Finally, some studies found ity of highly sensitive assays, is a particularly useful
marker of chronic, subclinical inflammation [63]. In theno differences in fibrinogen levels with respect to mi-
croalbuminuria in healthy subjects [53] and type 2 diabe- present study, we have shown that CRP levels were asso-
ciated with low level albuminuria as analyzed as a con-tes [58, 59]. These findings indicate that in patients with
diabetes, levels of fibrinogen seem to be particularly tinuous (ACR) as well as a dichotomous (microalbum-
inuria) variable. This association was attenuated withhigh with progression of the disease (as indicated by
macroalbuminuria [26, 55, 57] or retinopathy [55]). In adjustment for body fat and hypertension, whereas SI
did not show a significant impact on these relationships.nondiabetic populations, fibrinogen levels were signifi-
cantly elevated in the presence of microalbuminuria in In a previous report from the IRAS, we have shown an
independent association between SI and microalbuminu-two studies [52, 54], and in one other, fibrinogen was
also elevated but without reaching statistical significance ria [33], in contrast to the multivariate regression models
as shown on Table 4. In these latter models, however,(P , 0.1) [53]. These apparent discrepancies may be
explained by differences in sample size, populations stud- we have analyzed (1) additional independent variables
(smoking, use of ACE inhibitors, and, notably, the in-ied (nondiabetic vs. diabetic, severity of diabetes), and
statistical adjustments performed in order to account for flammatory markers); (2) a different measure of body fat
(waist circumference vs. BMI, the former being strongerdifferences in potentially confounding covariates.
In the present study, we demonstrate elevated fibrin- associated with SI); and (3) different populations (differ-
ent states of glucose tolerance vs. nondiabetic subjectsogen levels in subjects with microalbuminuria, even after
adjusting for various potential confounding factors, pre- exclusively).
We offer several possible explanations for our findingviously shown to determine both microalbuminuria and
fibrinogen levels, such as overall and central obesity, of an association of microalbuminuria with chronic in-
flammation. These explanations are not necessarily ex-hypertension, and insulin resistance.
Previous studies about the relationship of microalbu- clusive, and a considerable overlap presumably exists.
Furthermore, we would like to emphasize that becauseminuria with more specific inflammatory markers other
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of the cross sectional character of the present study, tion bias (normoalbuminuria vs. microalbuminuria). Sec-
ond, because of the relatively small number of subjectswe can only speculate about the causal and temporal
relationships between chronic inflammation and albu- with microalbuminuria, we may have missed significant
differences and relationships, especially in the subgroupminuria.
First, elevated levels of inflammatory markers may be analyses and in the multivariate statistical models.
Both CRP and microalbuminuria have been associ-the result of pre-existing atherosclerosis in subjects with
microalbuminuria. In nondiabetic as well as type 2 dia- ated with cardiovascular disease in a number of previous
studies. We have shown that chronic inflammation wasbetic subjects, microalbuminuria is associated with in-
creased cardiovascular morbidity and mortality [3–11], associated with microalbuminuria in diabetic as well as
nondiabetic subjects. We therefore propose chronic in-suggesting that in individuals with microalbuminuria,
atherosclerotic disease prevails. Second, elevations of flammation as a possible mediator between microalbumi-
nuria and macrovascular disease. However, these dataacute phase proteins and/or inflammatory cytokines may
directly alter glomerular function and thus be causally await confirmation in populations different from the
IRAS, and a number of new and critical questionsinvolved in the development of microalbuminuria. In
previous studies, urinary albumin excretion has been emerge. First, are levels of circulating inflammatory cyto-
kines indeed elevated in relationship to microalbuminu-elevated in inflammatory diseases [64–66] as well as in
a variety of acute syndromes, such as trauma, burn injury, ria in nondiabetic and/or diabetic populations? Is the
effect of currently available treatment shown to decreasesurgery, and acute myocardial infarction [8, 67–69].
Third, there is a potential link between inflammatory urinary albumin excretion in microalbuminuric patients
(such as antihypertensive drugs, particularly ACE inhibi-cytokines and glomerular function. Experimental data
suggest that tumor necrosis factor-a induces glomerular tors, improved glycemic control in patients with diabetes)
[51] at least partly mediated by inflammation? This ques-infiltration by leukocytes [70] and that IL-1 and tumor
necrosis factor-a influence the metabolism of glycosami- tion seems of particular interest in light of the results
of the Heart Outcomes Prevention Evaluation (HOPE)noglycans [71], which are components of the vascular
endothelium and the glomerular basement membrane trial, showing a beneficial effect of an ACE inhibitor on
the incidence of cardiovascular disease in a high-riskand are also involved in the etiology of microalbuminuria
[72] and possibly macrovascular disease [73]. Finally, population [76]. Finally, in nondiabetic as well as diabetic
microalbuminuria and elevated levels of inflammatory microalbuminuric subjects, is there a beneficial effect of
proteins may have a common antecedent, namely the anti-inflammatory treatment on urinary albumin excre-
increased elaboration of inflammatory cytokines. Inter- tion and maybe even macrovascular disease? Further
estingly, in a recent report from the Hoorn study, mi- studies are clearly needed to address these issues.
croalbuminuria and pre-existing atherosclerotic disease
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